Drug ID: 1d00000045
Drug Name: Alendronate
Generic Names: Poronil | Alenost | Denfos (70 mg) | Bifosa | Alendix | Ostogee -70 | Denfos | Restofos 70 | Denfos (35 mg) | Osteofos (70 mg) | Osteofos (5mg) | Alendix (70mg) | Bifosa (35 mg) | Alant | Zophost | Bifosa (10 mg) | Restofos | Osteofos (35 mg) | Bifosa (70 mg) | Dronal | Ralenost | Osteofos (10 mg) | Fosamax
Category: Bone Enhancers
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: The recommended dose is 5 to 10mg once daily or 35 to 70mg tablet once weekly.
Recommended In: This medication is a bisphosphonate, primarily used for prevention and treatment of osteoporosis in men and postmenopausal women. It is also used for Paget's disease and osteoporosis caused by steroid treatment. It reduces the amount of calcium released from the bones into the blood.
Directions For Use: It comes as a tablet, should be taken on an empty stomach.
Storage: Store it at room temperature and in an airtight container. Keep away from children and pets.
Dosage Forms: Tablet
Side Effects: Postmenopausal women
Gastrointestinal- Abdominal pain, nausea, indigestion, constipation, diarrhea, flatulence, acid regurgitation esophageal ulcer, vomiting, difficulty in swallowing and stomach inflammation.
Musculoskeletal - Bone, muscle/joint pain, muscle cramp and osteonecrosis of the jaw.
Central Nervous System - Headache and dizziness.
ENT- Taste perversion.
Gastrointestinal - Acid regurgitation, flatulence, heart burn, diarrhea, abdominal pain and nausea.
Body as a Whole - Hypersensitivity reactions, muscle pain, uneasiness, weakness and rarely fever.
Central Nervous system- Dizziness and fainting.
Skin- Rash (occasionally with photosensitivity), itching, hair loss, rarely severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Eye- Eye inflammation.
In Case of Overdose: No specific information is available on the treatment of overdosage with alendronate. Hypocalcemia, hypophosphatemia, and upper gastrointestinal adverse events, such as upset stomach, heartburn, esophagitis, gastritis, or ulcer, may result from oral overdosage. Milk or antacids should be given to bind alendronate. Due to the risk of esophageal irritation, vomiting should not be induced and the patient should remain fully upright.
Dialysis would not be beneficial.
Avoid If: Caution needed in patients with history of upper gastrointestinal disorders (discontinue if symptoms worsen); ulcers and active gastrointestinal bleeding.
Correct vitamin D and calcium deficiency before starting therapy.
Not recommended for use in patients with CrCl <35 ml/min.
Proper dental care is important while taking this medication.
Do not drive a car or operate machinery, avoid alcohol and smoking while taking this medication.
Contraindicated in patients with hypersensitivity, decreased level of calcium in blood, esophageal abnormalities and factors which delay esophageal emptying, severe kidney impairment, inability to stand or sit upright for more than half an hour, during pregnancy and breastfeeding.
It may cause severe bone, muscle, or joint pain.
Drug Interaction: Calcium Supplements/Antacids
Co-administration of Alendronate and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of Alendronate. Therefore, instruct patients to wait at least one-half hour after taking Alendronate before taking any other oral medications.
In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of Alendronate greater than 10 mg and aspirin-containing products.
Nonsteroidal Anti-Inflammatory Drugs
Since NSAID use is associated with gastrointestinal irritation, caution should be used during concomitant use with Alendronate.